IRCT20180826040869N3已完成3 期
Investigating the effect of memantine in preventing vasospasm in SAH patients with consciousness level 9-15
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age above 18 years
- •Visit within the first 24 hours of the onset of symptoms
- •Confirmation of subarachnoid hemorrhage by the plan's neurosurgeon (based on history, clinical findings and CT scan or brain MRI)
- •Patients with consciousness level 9 to 15
- •Consent of the patient or her legal guardian (in case of consciousness disorder) to participate in the study
排除标准
- •Lack of patient consent to participate in the study
- •Patients with a history of SAH or cerebral infarction
- •Patients diagnosed with hydrocephalus
- •Patients with secondary cerebral hemorrhage
- •History of allergy to memantine
- •Kidney failure stage 4 or 5 based on Acute Kidney Injury Network criteria (27)
- •Moderate to severe liver disease (Child-Pugh criteria, grade B and C) (28)
- •Having a history of epilepsy
- •History of dementia
- •The patient has a history of taking memantine in the last 6 months of pregnancy or breastfeeding
研究者
相似试验
已完成
3 期
Evaluation of the effect of memantine for the prevention of headaches caused by head traumapost traumatic headache.post traumatic headacheG44.3IRCT20201005048944N1Esfahan University of Medical Sciences90
招募中
3 期
Assessment the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathychemotherapy-induced peripheral neuropathy in patients with cancer.Idiopathic peripheral autonomic neuropathyG90.0IRCT20160310026998N12Tabriz University of Medical Sciences180
进行中（未招募）
不适用
Can memantine prevent memory impairment induced by MDMA in humans - Memantine-MDMAEUCTR2010-024543-33-NLMaastricht University
已完成
不适用
Can memantine prevent memory impairment induced by MDMA in humanscognitief functionerengeheugenproblemen en medierend mechanismeNL-OMON37941niversiteit Maastricht21
已完成
2 期
Memantine effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N2Vice chancellor for research, Mazandaran University of Medical Sciences50